Meet the Boston Heart Leadership Team
The Boston Heart leadership team is made up of accomplished medical, scientific and business leaders. Their combined experience and expertise drive our company towards its mission—enabling everyone to improve health and prevent disease.
Scott Madel, President
Scott has consistently provided insightful and innovative leadership for organizational turn-around and profitable growth across healthcare. He has launched novel technologies throughout diverse markets and geographies, spanning multiple payer channels and within various product categories for start-ups, market-leaders, and multi-nationals. Bringing broad strategic awareness and real-world solutions-based experience in clinical diagnostics, Scott is passionate about improving the delivery of patient-centric solutions which enable practitioners to address cardiometabolic disease with advanced testing.
Ernst J. Schaefer, MD, Founder and Chief Medical Officer
Dr. Schaefer is internationally recognized as a leader in the field of lipoprotein metabolism, and the diagnosis and management of lipoprotein disorders for the prevention of Coronary Heart Disease. He has made countless contributions to the National Cholesterol Education Program (NCEP) of the National Institutes of Health (NIH) and is a member of the National Lipid Association’s (NLA) Board of Directors.
Francine Wachtmann, VP Corporate Compliance
Francine joined Boston Heart Diagnostics in 2017 as the Vice President of Corporate Compliance. In this role, she serves as the Compliance and HIPAA Privacy Officer for the Laboratory. Additionally, Francine works with Boston Heart’s corporate parent, Eurofins, to support and advise on issues related to legal and regulatory compliance for all Eurofin’s US based Clinical Diagnostic Laboratories (“NDSC”).
Alex Abramov, SVP of Operations and Administration
Alex Abramov has served as Senior Vice President of Operations and Administration since May 2019. Before joining Eurofins, Mr. Abramov spent over 20 years in leadership roles within healthcare industry. He was a CFO at Byram Healthcare from 2015 to 2017 contributing to a successful sale of the company. Prior to Byram, Mr. Abramov spent over 15 years at Laboratory Corporation of America as a VP of Operations and Finance in Clinical Trials and Clinical Diagnostics divisions. He played an instrumental part in global expansion of LabCorp services and integration of Covance into LabCorp.
